Modulation of dendritic cell development by immunoglobulin G in control subjects and multiple sclerosis patients

Clinical and Experimental Immunology

Volumn 150, Issue 3, 2007, Pages 397-406

  Ohkuma, K ^a   Sasaki, T ^a   Kamei, S ^a   Okuda, S ^a   Nakano, H ^a   Hamamoto, T ^a   Fujihara, K ^b   Nakashima, I ^b   Misu, T ^b   Itoyama, Y ^b  

^a Kaketsuken   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adhesion molecules; Cell differentiation; Dendritic cells; IVIg; MS

Indexed keywords

ALPHA4 INTEGRIN; B7 ANTIGEN; BIOLOGICAL MARKER; CD40 ANTIGEN; CD83 ANTIGEN; CELL ADHESION MOLECULE; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 2; T6 ANTIGEN; VERY LATE ACTIVATION ANTIGEN 4;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD BRAIN BARRIER; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; IMMUNOMODULATION; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIGENS, CD; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; INTEGRIN ALPHA4; INTERLEUKIN-10; INTERLEUKIN-12; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 36048947605     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03496.x     Document Type: Article

References (48)

1. Bussel JB, Hilgartner MW. The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haemotologic disease. Br J Haematol 1984 56 : 1 7.
2. Panto F, Giordano C, Amato MP et al. The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients. J Autoimmun 1990 5 : 587 92.
3. Arsura EL, Bick A, Brunner NG, Grob D. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 1988 295 : 438 43.
4. Hsiao GR, Wolf RE, Kimpel DL. Intravenous immunoglobulin to prevent recurrent thrombosis in the antiphospholipid syndrome. J Clin Rheumatol 2001 7 : 336 9.
5. Akashi K, Nagasawa K, Mayumi T, Yokota E, Oochi N, Kusaba T. Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. J Rheumatol 1990 17 : 375 9.
6. Hilgartner MW, Bussel J. Use of intravenous gamma globulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia. Am J Med 1987 83 : 25 9.
7. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997 349 : 589 93.
8. Sorensen PS, Wanscher B, Jensen CV et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998 50 : 1273 81.
9. Achiron A, Gabbay U, Gilad R et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 1998 50 : 398 402.
10. Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 2002 9 : 557 63.
11. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989 143 : 4104 9.
12. Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992 62 : S82 6.
13. Zhang G, Lopez PH, Li CY et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004 127 : 1085 100.
14. Sharief MK, Ingram DA, Swash M, Thompson EJ. I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology 1999 52 : 1833 8.
15. Toyoda M, Zhang X, Petrosian A, Galera OA, Wang SJ, Jordan SC. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994 14 : 178 89.
16. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001 291 : 484 6.
17. Bussel JB. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 2000 37 : 261 6.
18. Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 1990 172 : 631 40.
19. Ludewig B, Odermatt B, Landmann S, Hengartner H, Zinkernagel RM. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med 1998 188 : 1493 501.
20. Kouwenhoven M, Ozenci V, Tjernlund A et al. Monocyte-derived dendritic cells express and secrete matrix-degrading metalloproteinases and their inhibitors and are imbalanced in multiple sclerosis. J Neuroimmunol 2002 126 : 161 71.
21. Pashenkov M, Soderstrom M, Huang YM, Link H. Cerebrospinal fluid affects phenotype and functions of myeloid dendritic cells. Clin Exp Immunol 2002 128 : 379 87.
22. Duddy ME, Dickson G, Hawkins SA, Armstrong MA. Monocyte-derived dendritic cells: a potential target for therapy in multiple sclerosis (MS). Clin Exp Immunol 2001 123 : 280 7.
23. Link H, Huang YM, Xiao BG. Dendritic cells in experimental allergic encephalomyelitis and multiple sclerosis. J Neuroimmunol 1999 100 : 102 10.
24. Huang YM, Xiao BG, Ozenci V et al. Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. J Neuroimmunol 1999 99 : 82 90.
25. Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001 2 : 585 9.
26. de Jong EC, Vieira PL, Kalinski P et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals. J Immunol 2002 168 : 1704 9.
27. Verbeek MM, Westphal JR, Ruiter DJ, de Waal RM. T lymphocyte adhesion to human brain pericytes is mediated via very late antigen-4/vascular cell adhesion molecule-1 interactions. J Immunol 1995 154 : 5876 84.
28. Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005 64 : 1336 42.
29. Brown KA, Bedford P, Macey M et al. Human blood dendritic cells: binding to vascular endothelium and expression of adhesion molecules. Clin Exp Immunol 1997 107 : 601 7.
30. - dendritic cell subsets differ in their cytokine production profiles, susceptibilities to transfection, and capacities to direct Th cell differentiation. J Immunol 2000 165 : 3584 91.
31. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995 182 : 389 400.
32. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998 392 : 245 52.
33. Fomsgaard A, Holder IA. Effect of a human IgG preparation rich in antibodies to a wide range of lipopolysaccharides on Gram-negative bacterial sepsis in burned mice. APMIS 1993 101 : 229 34.
34. Trautmann M, Held TK, Susa M et al. Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product. Clin Exp Immunol 1998 111 : 81 90.
35. Plumb J, Armstrong MA, Duddy M, Mirakhur M, McQuaid S. CD83-positive dendritic cells are present in occasional perivascular cuffs in multiple sclerosis lesions. Mult Scler 2003 9 : 142 7.
36. Pashenkov M, Teleshova N, Link H. Inflammation in the central nervous system: the role for dendritic cells. Brain Pathol 2003 13 : 23 33.
37. Bayry J, Lacroix-Desmazes S, Carbonneil C et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003 101 : 758 65.
38. Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 1997 90 : 3640 6.
39. Banki Z, Kacani L, Mullauer B et al. Cross-linking of CD32 induces maturation of human monocyte-derived dendritic cells via NF-kappa B signaling pathway. J Immunol 2003 170 : 3963 70.
40. Renschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996 14 : 233 58.
41. Karandikar NJ, Eagar TN, Vanderlugt CL, Bluestone JA, Miller SD. CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2000 109 : 173 80.
42. Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003 348 : 15 23.
43. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 354 : 899 910.
44. Lapointe BM, Herx LM, Gill V, Metz LM, Kubes P. IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 2004 127 : 2649 56.
45. Hofstetter HH, Ibrahim SM, Koczan D et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005 237 : 123 30.
46. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006 116 : 1218 22.
47. Gocke AR, Cravens PD, Ben LH et al. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol 2007 178 : 1341 8.
48. + T cells. Eur J Immunol 2005 35 : 3297 306.